{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.18","upperLimit":"1.61","value":"1.396"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"TTR was defined for participants with confirmed objective response (sCR,CR,VGPR and PR) as the time from first date of study intervention to the date of first documentation of objective response. sCR: CR and normal sFLC ratio with absence of clonal cells in BMB/BMA by immunohistochemistry, immunofluorescence or flow cytometry.CR: negative immunofixation on serum and urine,disappearance of soft tissue plasmacytoma, \\<5% plasma cells in BMA, if disease measured by sFLC only,preceding criteria plus normal sFLC ratio.VGPR:Serum and urine M-protein detectable by immunofixation but not on electrophoresis; or \\>=90% reduction in serum and urine M-protein level \\<100mg/24h.PR:\\>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \\>=90% or \\<200 mg/24h.If serum and urine M-protein unmeasurable,VGPR \\& PR: \\>=90%,\\>=50% decrease in difference respectively between involved and uninvolved sFLC levels,if present at baseline,\\>=90%, \\>=50% reduction in soft tissue plasmacytomas' size.","dispersionType":"Full Range","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"MEDIAN","populationDescription":"SAS included all enrolled participants who received at least 1 dose of study intervention. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From date of first dose to the first documentation of objective response that is subsequently confirmed (maximum of 65.1 weeks of treatment)","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"Months"}